Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-015304
Filing Date
2024-11-12
Accepted
2024-11-12 16:01:46
Documents
65
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q vygr-20240930x10q.htm   iXBRL 10-Q 1674213
2 EX-10.1 vygr-20240930xex10d1.htm EX-10.1 58495
3 EX-10.2 vygr-20240930xex10d2.htm EX-10.2 32465
4 EX-31.1 vygr-20240930xex31d1.htm EX-31.1 13698
5 EX-31.2 vygr-20240930xex31d2.htm EX-31.2 13788
6 EX-32.1 vygr-20240930xex32d1.htm EX-32.1 10736
  Complete submission text file 0001558370-24-015304.txt   6996154

Data Files

Seq Description Document Type Size
7 EX-101.SCH vygr-20240930.xsd EX-101.SCH 42382
8 EX-101.CAL vygr-20240930_cal.xml EX-101.CAL 48826
9 EX-101.DEF vygr-20240930_def.xml EX-101.DEF 193181
10 EX-101.LAB vygr-20240930_lab.xml EX-101.LAB 370096
11 EX-101.PRE vygr-20240930_pre.xml EX-101.PRE 305032
68 EXTRACTED XBRL INSTANCE DOCUMENT vygr-20240930x10q_htm.xml XML 1280989
Mailing Address 75 HAYDEN AVENUE LEXINGTON MA 02421
Business Address 75 HAYDEN AVENUE LEXINGTON MA 02421 857-259-5340
Voyager Therapeutics, Inc. (Filer) CIK: 0001640266 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37625 | Film No.: 241447779
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)